Catestatin levels in moderate-to-severe acne
Assessment of Serum Catestatin Level in Acne Vulgaris Patients Before and After Treatment With Oral Isotretinoin
This test will measure blood levels of the peptide catestatin in people with moderate to severe acne who are treated with isotretinoin.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Aswan University Academic / other |
| Locations | 1 site (Aswān) |
| Trial ID | NCT07054398 on ClinicalTrials.gov |
What this trial studies
Acne vulgaris is a common inflammatory condition driven by sebum, keratinization changes, and inflammatory mediators. This interventional program enrolls people with moderate to severe acne who will receive standard oral isotretinoin while investigators measure serum catestatin levels at baseline and during treatment. Participants with pregnancy, lactation, recent systemic acne therapy, immunocompromise, or certain comorbidities are excluded. The work is conducted at Aswan University Hospital and aims to link catestatin patterns with acne severity and treatment course.
Who should consider this trial
Good fit: Adults of both sexes with moderate or severe acne who are eligible for isotretinoin and do not meet exclusion criteria (for example pregnancy, recent systemic acne therapy, immunosuppression, or relevant medical comorbidities).
Not a fit: People with mild or purely non-inflammatory acne, pregnant or breastfeeding individuals, immunocompromised patients, or those with excluded medical conditions or recent systemic acne treatment are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, catestatin measurements might help indicate disease activity or treatment response and guide more personalized acne care.
How similar studies have performed: This is a relatively novel biomarker approach for acne: few prior clinical studies have examined catestatin in acne, so clinical benefit is not yet established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy persons of both sexes with moderate and severe acne. Exclusion Criteria: * Pregnant and lactating women. * Immunocompromised patients. * Severe anemia. * History of chronic liver disease. * Hyperlipidemia * Non-inflammatory acne conditions. * History of neurologic disorders. * History of neoplastic disorders. * History of cardiac disease. * History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks. * Cases with known hypersensitivity reaction to isotretinoin.
Where this trial is running
Aswān
- Aswan Unuversity Hospital — Aswān, Egypt (Recruiting)
Study contacts
- Study coordinator: Mona Zakaria Mohamed, MSc
- Email: mona1704213@aswu.edu.eg
- Phone: +201142550119
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.